Bayer’s Share Price Doubles in a Year, But Net Debt Hits €32.5 Billion and Cash Flow Turns Sharply Negative
Published on 07/06/2026 at 09:13 | Redaktion boerse-global.de
Bayer’s stock has staged a breathtaking recovery, rallying more than 100% over the past twelve months and pushing the share price to a fresh multi-year high above €53. The surge, fuelled by a series of legal breakthroughs and a strategic restructuring of its US glyphosate operations, stands in stark contrast to the company’s deteriorating financial health. Behind the market euphoria, the German conglomerate’s net financial debt swelled to €32.5 billion at the end of March — a 9% increase from year-end levels — while free cash flow sank deeper into negative territory.
The rally accelerated in late June after the US Supreme Court overturned a Missouri state court ruling that had previously exposed Bayer to thousands of additional lawsuits over alleged inadequate warning labels on its Roundup herbicide. The decision, handed down on 26 June 2026, effectively blocks a broad swathe of claims and provided a major catalyst for the stock. Within days, Deutsche Bank analysts raised their price target from €45 to €60 and upgraded the stock from “Hold” to “Buy,” citing the reduced legal overhang. On Friday, Bayer’s shares closed at €53.04, just 1.52% below the 52-week high of €53.86.
The company also moved to ring-fence its US glyphosate business by creating a new subsidiary called Ruveon LLC, officially launched on 1 July 2026. The spin-off is designed to isolate future legal risks from the core operations, though analysts caution that claims related to defective product design or negligence could still surface. Old liabilities, such as those tied to the blood-clotting drug Trasylol, periodically re-emerge in the media, serving as a reminder that organisational separation does not instantly erase financial exposure.
Should investors sell immediately? Or is it worth buying Bayer?
The stock’s technical indicators, however, flash warning signals. The relative strength index (RSI) has soared to 85.1 — a level that typically marks extreme overbought conditions for a blue-chip stock of Bayer’s size. The price now trades 42.91% above its 200-day moving average of €37.11, a historical anomaly that often precedes a sharp pullback or a prolonged consolidation phase. The 50-day moving average stands at €38.86, and analysts see a breach below that level as the first sign of a corrective move.
While the market cheered the legal wins, the underlying cash flow picture tells a more sobering story. In the first quarter alone, Bayer’s free cash flow plunged to minus €2.3 billion, compared with a negative €1.5 billion in the same period last year. The main culprit was a relentless outflow of roughly €2 billion in legal settlement payments — mostly related to the glyphosate and PCB lawsuits that continue to drain the balance sheet. The management, led by chief financial officer Wolfgang Nickl, has reaffirmed its full-year forecast of free cash flow between minus €1.5 billion and minus €2.5 billion for 2026, a range that already incorporates about €5 billion in legal costs.
Net debt is expected to stay stubbornly high, with Bayer budgeting for a year-end figure between €32 billion and €33 billion. That means even as the stock has more than doubled, the company’s leverage remains near record levels. The disconnect between market sentiment and financial reality is stark: the share price has surged 47.54% in the past month alone, 39.49% year-to-date, and an eye-popping 103.57% over twelve months — one of the strongest moves in the entire German equity market this year.
On the bearish side, the technical overhang is not the only risk. Uncertainty over the remaining lawsuit categories persists, and the Ruveon restructuring may not shield Bayer from all forms of litigation. Additionally, planned reforms in German healthcare policy are weighing on the sector, with some pharmaceutical companies already scaling back their investments in the country. In the short term, the 52-week high of €53.86 will act as a critical resistance level. If the stock can break decisively above that threshold, the path opens towards the Deutsche Bank target of €60. But if the overbought RSI triggers profit-taking, the first key support lies at the 50-day moving average of €38.86 — a level that would represent a significant correction from current prices.
Ad
Bayer Stock: New Analysis - 6 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
